Radiation Oncology

Patient Information

Our Physicians

Treatment Machines

Hours of Operation

RTOG Research Protocols

Other Research Protocols

    Head & Neck

    Prostate

Residency Application

Physics

Biology

Atlas of Organs at Risk

Remote Support

Remote Support
OnCampus

Lung Protocols

• RTOG 0213 A PHASE I/II TRIAL OF A COX-2 INHIBITOR, CELEBREX™ (CELECOXIB), [NSC# 719627] WITH LIMITED FIELD RADIATION FOR INTERMEDIATE PROGNOSIS PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER, WITH ANALYSIS OF PROGNOSTIC FACTORS
  PI: Ivan Kessel  Eligibility   Schema
   

• RTOG 0214 A PHASE III COMPARISON OF PROPHYLACTIC CRANIAL IRRADIATION VERSUS OBSERVATION IN PATIENTS WITH LOCALLY ADVANCED
  NON-SMALL CELL LUNG CANCER
  PI: Ivan Kessel  Eligibility  Schema
   

• RTOG 96-16 PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG
  Eligibility Schema
   

• RTOG 99-09 PHASE II STUDY OF POSTOPERATIVE ADJUVANT IMMUNOTHERAPY AND RADIATION IN PATIENTS WITH COMPLETELY RESECTED STAGE II AND STAGE IIIA NON-SMALL CELL LUNG CANCER
  Eligibility Schema
   

• RTOG L-0127 PHASE III CHEMOPREVENTION TRIAL OF SELENIUM SUPPLEMENTATION IN PERSONS WITH RESECTED STAGE I NON SMALL CELL LUNG CANCER NOT OPEN TO ENROLLMENT at UTMB
  Protocol Schema
   

• RTOG L-0017; A PHASE I STUDY OF GEMCITABINE, CARBOPLATIN OR GEMCITABINE, PACLITAXEL AND RADIATION THERAPY FOLLOWED BY ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
  Eligibility Schema
   

• RTOG L-0117; A PHASE I/II DOSE INTENSIFICATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY AND CONCURRENT CHEMOTHERAPY FOR PATIENTS WITH INOPERABLE, NON-SMALL CELL LUNG CANCER
  Eligibility Schema
   

• RTOG 0241; PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 Gy) OR ONCE DAILY THORACIC RADIOTHERAPY (70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER
  Eligibility Schema
   

• CTSU NCIC BR.19; A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (Iressa) in Completely Resected Stage IB, II, and IIIA Non-Small Cell Lung Cancer
  Eligibility Schema